Last reviewed · How we verify
NCT01624532: GC1109
A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109
Phase 2 trial testing GC1109 or Placebo of GC1109 in Anthrax in 240 participants. Completed in 19 December 2022.
2 August 2022
Quick facts
| Lead sponsor | Green Cross Corporation |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 240 |
| Start date | 14 July 2021 |
| Primary completion | 2 August 2022 |
| Estimated completion | 19 December 2022 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- GC1109 or Placebo of GC1109 — full drug profile →
Conditions studied
- Anthrax — all drugs for Anthrax →
Sponsor
Green Cross Corporation — full company profile →
Who can join
Adults 19 to 65, any sex, with Anthrax. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109 Administered in Multi Intramuscular Doses to Healthy Subjects.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Current State of Anthrax Vaccines and Key R&D Gaps Moving Forward.
Clark A, Wolfe DN. · · 2020 · cited 18× · PMID 32365729 · DOI 10.3390/microorganisms8050651 -
Biological threat preparedness through vaccine development and stockpiling: challenges and strategic implications.
Lee J. · · 2025 · cited 1× · PMID 40529698 · DOI 10.3389/fpubh.2025.1614626 -
Human anthrax vaccines: Current status and future prospects.
Qiao Z, Wang S, Shi Y, Zhu L, et al · · 2025 · PMID 41381214 · DOI 10.1080/21645515.2025.2595774
Verify or expand the search:
- PubMed search for NCT01624532
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Anthrax
Currently open trials in the same condition.
- NCT06365073 — A Case-control Study on the Clinical Characteristics of 28-day and 90-day Death From Severe Anthrax · recruiting
- NCT00050310 — Natural History of Anthrax: a Study of Primary Infected, Recovered, and Exposed Individuals (SPoRE); and Evaluation of A · recruiting
Other Green Cross Corporation trials
Trials by the same sponsor.
- NCT04555148 — COVIDIG (COVID-19 Hyper-ImmunoGlobulin) · Phase 2 · completed
- NCT04175522 — Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis: · Phase 2 · completed
- NCT03947138 — A Study of GC3107(BCG Vaccine) in Healthy Infants · Phase 3 · completed
- NCT03492710 — Study of Immune Globulin Intravenous (Human) GC5101F in Subjects With Primary Humoral Immunodeficiency · Phase 3 · withdrawn
- NCT04003844 — Study of Combined Therapy IVIG-SN 10% and Acetylsalicylic Acid in Kawasaki Disease · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01624532 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Green Cross Corporation
- Last refreshed: 4 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01624532.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing